Biopharmaceutical Haiku

2/3/14

Patients ask doctors

Can you sequence my genome?

Enter brave new world

 

One word description

Newly approved cancer drugs

Unaffordable

 

Hot biotech trend

Virtual drug companies

Who will do research?

 

Can’t be denied now

Obamacare launch shaky

Improvements needed

 

Biosimilars

Challenges remain ahead

Gold mine, or fools gold?

 

Hype is well deserved

Immunotherapy soars

Keeping fingers crossed

 

Big pharma layoffs

World of hurt for smart people

Fries with that burger?

 

Payments to docs stopped

GSK sets example

Will others follow?

 

Orphan diseases

Big Pharma disdained, now loves

New hope for the few

 

IPO window

Best jump through it while you can

May close tomorrow

 

Drug regulations

Disliked by industry but

Safety paramount

 

Best research advice

Embrace collaborations

Experts can help you

 

Antibiotics

Still desperately needed

Bacteria change

 

Inevitable

Mergers and acquisitions

Good for some, not all

 

Healthcare in U.S.

Broken system needs repair

Wish I lived in France

 

Hot technology

CRISPR – Can fix broken genes

Godsend if it works

 

Next blockbuster drugs

Cholesterol lowering

Outcomes not required?

 

Pharma mindset changed

Who is our customer now?

Patient or payer?

 

Schekman wins Nobel

Goodbye Cell, Science, Nature

Easy for him to say

 

Can’t afford your meds?

Insurance copays too high?

Hello Canada

 

 

Feel free to add your own haiku in the comments section below!

 

Stewart Lyman is Owner and Manager of Lyman BioPharma Consulting LLC in Seattle. He provides strategic advice to clients on their research programs, collaboration management issues, as well as preclinical data reviews. Follow @

By posting a comment, you agree to our terms and conditions.